
XyloCor financing advances one-time cardiovascular gene therapy
XyloCor Therapeutics has completed a $67.5 million Series B financing to support a Phase IIb clinical trial (EXACT‑2) of XC001 (encoberminogene rezmadenovec) in refractory angina. The trial will use a new non‑surgical method of endocardial administration via a novel injection catheter. The financing will also fund a Phase II trial… Read More
